Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Eustace A. Serafetinides"'
Autor:
Wolfgang Huber, Mervin L. Clark, Anthony W. Czerwinski, Eustace A. Serafetinides, Celia Perrier
Publikováno v:
Clinical Pharmacology & Therapeutics. 15:436-441
Publikováno v:
Clinical Pharmacology & Therapeutics. 11:680-688
Publikováno v:
The Journal of Clinical Pharmacology and New Drugs. 11:304-309
Publikováno v:
Journal of neurology, neurosurgery, and psychiatry. 25
Autor:
Eustace A. Serafetinides, H. Rudy Ramsey, Don K. Rahhal, Mervin L. Clark, Robert E. Ragland, J. Paul Costiloe
Publikováno v:
Psychopharmacologia. 18(3)
Fixed daily doses of chlorpromazine (CPZ), in the amounts of 150, 300, and 600 mg were administered orally to chronic schizophrenic inpatients for 24 weeks while psychiatric and ward behavioral responses were monitored at regular intervals. It was fo
Autor:
J. Robert Hewson, George A. Braun, John P. Colmore, Don K. Rahhal, Eustace A. Serafetinides, Mervin L. Clark
Publikováno v:
Clinical pharmacology and therapeutics. 9(3)
Autor:
William Trousdale, Kanellos D. Charalampous, Wolfgang K. Huber, Eustace A. Serafetinides, Mervin L. Clark, John P. Colmore
Publikováno v:
Archives of General Psychiatry. 25:404
The attempt in one hospital to model a drug study after the NIMH nine-hospital collaborative study resulted in a useful modification in which relatively small numbers of newly admitted, acutely exacerbated chronic schizophrenic patients were studied
Autor:
Mervin L. Clark, Don K. Rahhal, J. Paul Costiloe, H. Rudy Ramsey, Fredda D. Wood, Eustace A. Serafetinides
Publikováno v:
Archives of General Psychiatry. 27:479
Behavioral data from a previous study were stratified by age ( 40 years) and duration of hospitalization ( 10 years) and examined for dose-response relationships at the 12th week of treatment with either placebo or 150, 300, or 600 mg chlorpromazine